Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection
Recall D-0130-2023, part of FDA recall event 91378. See Pine Pharmaceuticals's company page.
Pine Pharmaceuticals, LLC started this Class II drug recall on Dec 22, 2022 (voluntary: firm initiated); FDA lists it as terminated, terminated May 4, 2023.
- Classification: Class II
- Started: Dec 22, 2022
- Status: Terminated
CGMP Deviations: Raw material recalled by repackager, due to discoloration.
- Product
- Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Single Dose Vial, Compounded by Pine Pharmaceuticals, 355 Riverwalk Pkwy, Tonawanda, NY 14150. NDC 69194-0948-1
- Quantity
- 11,453 vials
- Lots and codes
- Lot # 62881, Exp 12/25/2022; 62923, Exp 12/26/2022; 63066, Exp 01/03/2023; 63067, Exp 01/01/2023; 63103, Exp 01/02/2023; 63120, Exp 01/03/2023; 63219, 63226, Exp 01/08/2023; 63263, Exp 01/09/2023; 63380, 63381, Exp 01/15/2023; 63433, Exp 01/16/2023; 63455, Exp 01/17/2023; 63537, Exp 01/22/2023; 63580, Exp 01/23/2023; 63721, Exp 01/29/2023; 63792, Exp 01/31/2023; 63888, Exp 02/05/2023; 63930, Exp 02/06/2023; 63959, Exp 02/07/2023; 64079, Exp 02/13/2023; 64109, Exp 02/14/2023; 64239, Exp 02/21/2023.
- Distribution
- Nationwide to medical facilities.
- Recalling firm
- Pine Pharmaceuticals, LLC, Tonawanda, NY, United States
- How the firm notified
- FDA classified
- Jan 13, 2023
Newest first, one product per recall event; search them all
- Tropi-Phen (tropicamide 1%, phenylephrine 2.5%) ophthalmic solution, 5mL multi-use dropper, Rx only, Compounded by Pine…D-0063-2024 · Class II · Oct 2, 2023 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports